 |
Keyword Search |
|
|
|
| |
|
|
|
 | Event ID : ADDF
Alzheimers Drug Discovery Foundation
4th DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE
Houston, TX
February 1-2, 2010
ABOUT THE
MEETING
The purpose of the
conference is to
advance drug
discovery for
neurodegenerative
diseases by
educating scientists
on the process of
translating basic
research into novel
therapies. Speakers and chairs
present lectures and
case studies on Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, ALS, MS,
and other orphan
neurological
diseases. 
COURSE
OBJECTIVES
-
Discuss the
principles of drug
discovery for
neurodegenerative
disease.
-
Exchange ideas,
knowledge and
resources about drug
discovery for
neurodegenerative
disease.
-
Stimulate
pre-clinical
research in the
discovery and
testing of novel
compounds aimed at
the prevention and
treatment of
neurodegenerative
disease.
-
Build public-private
partnerships that
will accelerate drug
discovery for
neurodegenerative
disease.
TARGET
AUDIENCE
-
Academic and industry
scientists engaged in
drug discovery research
for neurodegenerative
diseases or CNS
-
Business development
and licensing
professionals
-
Alliance management
professionals
-
Venture capitalists
and other investors.
For more information visit: http://www.worldeventsforum.com/addf/2010/index.html |
| | 4th DRUG DISCOVERY FOR NEURODEGENERATION | | | |
Objectives :
The purpose of the conference is to advance drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies.
Speakers and chairs present lectures and case studies on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, MS, and other orphan neurological diseases.
|
______________________
Overview of Drug Discovery for Neurodegenerative Disease
Speaker(s) : Howard Fillit, MD
______________________
Stem Cells to Accelerate Drug Discovery for Neurodegenerative Disease
Speaker(s) : Lee Rubin, PhD
| | I. Basics of Medicinal Chemistry | | | |
Objectives :
The goal of this session is to review fundamentals of medicinal chemistry relevant to drug discovery for CNS disorders. Although the focus is on small molecule drugs, due to the extensive state of knowledge, general themes relevant to peptide and protein therapeutics will also be discussed. The attendee should leave the session with a practical, working familiarity of contemporary approaches and key issues that should be considered by interdisciplinary teams as they take hits to lead compounds to candidate small molecule therapeutics.
|
______________________
Overview: Medicinal Chemistry Rules of Thumb, Myths and Realities in CNS Drug Discovery
Speaker(s) : D. Martin Watterson, PhD
______________________
Designing Small Molecules with Increased Potential for CNS Penetration
Speaker(s) : Laura Chico, MS, PhD
______________________
Synthetic Chemistry Essentials for Biologists
Speaker(s) : Heather Behanna, PhD
| | II. In-vitro Testing: Early Phases of Drug Discovery | | | |
Objectives :
A key component of the development of new therapeutic agents is the identification of molecules that can serve as initial lead structures on which drug discovery programs can be built. High-throughput screening of large collections of drug-like molecules for modulatory activity in disease-relevant assays is an important means to discovering these lead molecules. This session will first address strategies for selecting your target, then the development of assays that are suitable for high-throughput screening and for secondary assays to validate the primary screening results. Most drug development efforts fail due to toxicity and ADME (absorption, distribution, metabolism and excretion) properties. This session will end with a presentation on technology used for in vitro toxicity and ADME testing.
|
______________________
Developing Relevant High-Throughput Assays for the Identification of Potential Drug Candidates
Speaker(s) : Marcie Glicksman, PhD
______________________
Role of In Vitro Models in Drug Discovery for Neurodegenerative Disease
Speaker(s) : Lisa Minor, PhD
______________________
In Vitro Toxicity Testing: What, Why & How
Speaker(s) : Karen L. Steinmetz, PhD, DABT
| | III. Pre-Clinical Proof-of-Concept & Development | | | |
Objectives :
Preclinical development, the phase of drug
development between discovery and clinical trial, is
often referred to as the “Valley of Death”. Several
factors contribute to this barren landscape. Many
promising leads fail due to problems of formulation,
delivery, bioavailability, scalable manufacturing,
or safety. Investigators seeking to navigate past
these hazards also encounter challenges in funding,
resources, and expertise. This session offers an
overview of the steps involved in optimization of a
lead compound and in vivo efficacy
and safety studies that determine dosing
strategies. Presentations will include examples of
go/no-go stage decision points, funding resources,
and outsourcing options to complete the journey of
discovery to an Investigational New Drug (IND)
application for clinical trial.
|
______________________
Requirements for a Lead Compound to Become a Clinical Candidate
Speaker(s) : Nancy Wehner, PhD
______________________
Behavioral Testing in Neurodegenerative Disease
Speaker(s) : Taleen Hanania, PhD
______________________
Regulatory Requirements & Strategy
Speaker(s) : Joy Cavagnaro, PhD
______________________
The Basics of Pre-Clinical Development
Speaker(s) : Edward Spack, PhD, MS
| | IV. Issues in Technology Transfer: Interactions and Intellectual Property | | | |
Objectives :
This session will focus on the interactions among
academic researchers, their technology transfer
office and industry partners. An introduction will
discuss the various roles and responsibilities of
all of the parties involved and hope to begin to
demystify academic – industry relations. The basics
of patents will be presented with an emphasis on
what they can and cannot successfully cover, as well
as what a researcher needs to do to maximize the
chances of a positive outcome. A variety of
agreements used in academic – industry relationships
will also be discussed, with an emphasis on the
importance of creating a good relationship amongst
all parties. The session will continue with an
honest appraisal of the good, the bad and the ugly
of new company formation in the biotech industry,
and finally close with an industry perspective on
dealing with academic institutions.
|
______________________
Working Effectively with Your TTO: Roles and Responsibilities
Speaker(s) : Kathleen Denis, PhD
______________________
Intellectual Property 101: A Primer For Investigators
Speaker(s) : Colin G. Sandercock
______________________
Creating Relationships with Industry: Consulting, Research, MTA
Speaker(s) : Louis Berneman, EdD, CLP
______________________
Should You Start a Biotechnology Company?
Speaker(s) : John S. Swartley, PhD
______________________
What Companies Look for in a Licensing Partner
Speaker(s) : Susan P. Rohrer, PhD
| | VI. Resources and Services For Advancing Drug Discovery | | | |
Objectives :
This session will focus on descriptions of the
resources available through a variety of mechanisms
within academia, the National Institutes of Health (NIH),
foundations and commercial vendors. Speakers will
focus on resources for assay development, target
identification, drug discovery, drug development,
pre-clinical toxicology evaluation and other
components needed for the translation of
pre-clinical drug candidates into potential
therapies tested in clinical trials. In particular,
it will include specific descriptions of programs
available to academic investigators through
individual NIH Institutes, including the National
Institute on Aging (NIA) and the National Institute
of Neurological Disorders and Stroke (NINDS), as
well as trans-NIH programs including the NIH Roadmap
for Medical Research and the NIH Blueprint for
Neuroscience Research.
|
______________________
How to Outsource Early Drug Discovery
Speaker(s) : Mark Creswell, PhD
______________________
Resources at the National Institute of Health
Speaker(s) : William Matthew, PhD
______________________
Types of Academic Drug Discovery Programs
Speaker(s) : Euan Ramsey, PhD
______________________
Foundation Resources
Speaker(s) : Howard Fillit, MD , Leticia M. Toledo-Sherman, PhD , Tim Coetzee, PhD, MS
- Venture Philanthropy—Howard Fillit, MD, ADDF; Other Philanthropic Approaches — Tim Coetzee, PhD, MS Fast Forward; Funding and other challenges for rare diseases — Leticia M. Toledo-Sherman, PhD, CHDI Foundation
|
|
|
